Business Wire

OpenGate Capital Fully Exits Investment in EverZinc

1.6.2022 22:00:00 EEST | Business Wire | Press release

Share

OpenGate Capital, a global private equity firm, announced that it has exited its investment in EverZinc, a global provider of specialty zinc materials, through a sale to U.S. Zinc, a portfolio company of Aterian Investment Partners. Terms of the investment were not disclosed.

EverZinc is headquartered in Liège, Belgium and has industrial operations in Belgium, Canada, the Netherlands, Norway, China, and Malaysia. EverZinc specializes in four product lines: fine zinc powders, zinc oxide, zinc for batteries, and Zano®, an ultra-fine zinc oxide. EverZinc products are sold to customers around the world for use in a variety of applications, including anti-corrosion paints, tires, pharmaceutical chemicals, ceramics and glass, and sunscreens.

The business is led by CEO, Vincent Dujardin, and was acquired by OpenGate Capital in 2016 through a corporate carve-out from Umicore. During OpenGate’s ownership, EverZinc grew EBITDA by 2x, and expanded its product mix and geographic footprint, all while further strengthening its ESG attributes.

Julien Lagrèze, OpenGate Partner and Head of Europe, commented on the transaction, stating, “When we acquired EverZinc, we believed the business had tremendous potential for geographic expansion and innovation, and, under Vincent’s leadership, new products were developed and new markets penetrated, which re-positioned the company for growth and enhanced profitability. It has been a truly rewarding experience working with Vincent and his team, and we’re confident that EverZinc is in great hands as it embarks on a new phase of growth.”

EverZinc will join U.S. Zinc, a global zinc chemistry and material science business, manufacturing diversified zinc products including zinc oxide, zinc powder, and zinc metal used in end markets such as tires, chemicals, coatings, and agriculture.

Commenting on the sale, Dujardin stated, “I am incredibly proud of leading EverZinc, which is an innovative, diverse, and global business that is supported by an incredibly dedicated team of people. I am confident that the business will have much success with U.S. Zinc.”

Jefferies served as lead financial advisor and Stifel served as financial advisor to OpenGate Capital.

About OpenGate Capital

OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation, and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build, and scale successful businesses. To date, OpenGate Capital has executed 40 acquisitions across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

OpenGate Media Contacts
Prosek Partners
Email: Pro-opengate@prosek.com

Alanna Chaffin
Co-Head, Investor Relations & Communications
Email: AChaffin@opengatecapital.com
Telephone: +1 310-432-7000

OpenGate Business Development Contact
Joshua Adams
Email: jadams@opengatecapital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 17:00:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application and scale, we are well-positioned to help our customers translate th

Andersen Consulting Strengthens Capabilities with Addition of Lukkap31.3.2026 16:30:00 EEST | Press release

Andersen Consulting adds collaborating firm Lukkap, a consultancy focused on experience-driven capabilities aligned with clients’ evolving people, customer, and digital transformation needs. Founded in 2009 and headquartered in Spain, Lukkap delivers integrated solutions that help organizations transform how they serve customers, engage employees, and unlock value through behavioral insights and data analytics. The firm’s multidisciplinary approach spans customer journey redesign, high-impact employee experience programs, talent and leadership development, predictive analytics, and comprehensive outplacement and transition services. Lukkap works across sectors — including healthcare, pharmaceutical, consumer goods, retail, finance, and banking — to build human-centered strategies that drive measurable business results. “By combining our experience-led methodology with Andersen Consulting’s global platform, we can accelerate the way organizations approach customer experience,” said Albe

Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 16:26:00 EEST | Press release

Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under

HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 16:25:00 EEST | Press release

HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t

Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 16:00:00 EEST | Press release

Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartner. “By redefining partner marketing automation and embedding it directly into our revenue orchestration platform, we en

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye